company background image
BOT logo

Botanix Pharmaceuticals CHIA:BOT Stock Report

Last Price

AU$0.39

Market Cap

AU$717.9m

7D

4.7%

1Y

137.9%

Updated

24 Dec, 2024

Data

Company Financials +

Botanix Pharmaceuticals Limited

CHIA:BOT Stock Report

Market Cap: AU$717.9m

BOT Stock Overview

Engages in the research and development of dermatology and antimicrobial products in Australia and the United States. More details

BOT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 95.1% below our estimate of its fair value

Earnings are forecast to grow 99.39% per year

Risk Analysis

Does not have meaningful revenue (A$2M)

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

Botanix Pharmaceuticals Limited Competitors

Mayne Pharma Group

ASX:MYX

AU$379.0m

Syntara

ASX:SNT

AU$105.8m

Clarity Pharmaceuticals

ASX:CU6

AU$1.3b

Neurizon Therapeutics

ASX:NUZ

AU$80.3m

Price History & Performance

Summary of share price highs, lows and changes for Botanix Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.39
52 Week HighAU$0.45
52 Week LowAU$0.16
Beta1.93
1 Month Change23.62%
3 Month Change7.53%
1 Year Change137.88%
3 Year Change613.64%
5 Year Change390.63%
Change since IPO1,208.33%

Recent News & Updates

Recent updates

Shareholder Returns

BOTAU PharmaceuticalsAU Market
7D4.7%-6.9%-0.5%
1Y137.9%-10.6%8.2%

Return vs Industry: BOT exceeded the Australian Pharmaceuticals industry which returned -10.6% over the past year.

Return vs Market: BOT exceeded the Australian Market which returned 8.2% over the past year.

Price Volatility

Is BOT's price volatile compared to industry and market?
BOT volatility
BOT Average Weekly Movement7.2%
Pharmaceuticals Industry Average Movement10.3%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market3.1%

Stable Share Price: BOT has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: BOT's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1984n/aHowie McKibbonwww.botanixpharma.com

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.

Botanix Pharmaceuticals Limited Fundamentals Summary

How do Botanix Pharmaceuticals's earnings and revenue compare to its market cap?
BOT fundamental statistics
Market capAU$717.90m
Earnings (TTM)-AU$13.87m
Revenue (TTM)AU$2.07m

346.9x

P/S Ratio

-51.8x

P/E Ratio

Is BOT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOT income statement (TTM)
RevenueAU$2.07m
Cost of RevenueAU$3.65m
Gross Profit-AU$1.58m
Other ExpensesAU$12.29m
Earnings-AU$13.87m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0076
Gross Margin-76.48%
Net Profit Margin-670.20%
Debt/Equity Ratio0%

How did BOT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 14:06
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Botanix Pharmaceuticals Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter